Posted On: 11/15/2016 10:21:31 AM
Post# of 72447
Dr. B: 3 categories of drugs. First, P
currently in Phase 2, 505B2 pathway
Kevetrin, Phase 2A starting for ovarian
Bilacidin, fast track designations.
Shows slide of various areas, and which pursued now and which are in future.
Some overlap between dermatology and cancer (Bril-OM)
Want to use Bril-UP for Crohn's disease
Next slide: mid-phase company re clinical developments. "We leverage various designations to expedite development" -- orphan drug, fast track, etc
Chart of upcoming clinical milestones: distributed among various programs. Will be catalysts for growth.
Psoriasis and UP: have delivered already on them
Also first interim analysis on UP trial.
Anticipate ovarian 2A trial (mechanism of action) will start later this quarter or early 2017.
1st half 2017: Prurisol interim analysis, OM interim analysis, complete Phase 2 of UP. Then Phase 2 of psoriasis and K proof of concept, and the OM trial
ABSSSI study: timetable depends on FDA agreement.
currently in Phase 2, 505B2 pathway
Kevetrin, Phase 2A starting for ovarian
Bilacidin, fast track designations.
Shows slide of various areas, and which pursued now and which are in future.
Some overlap between dermatology and cancer (Bril-OM)
Want to use Bril-UP for Crohn's disease
Next slide: mid-phase company re clinical developments. "We leverage various designations to expedite development" -- orphan drug, fast track, etc
Chart of upcoming clinical milestones: distributed among various programs. Will be catalysts for growth.
Psoriasis and UP: have delivered already on them
Also first interim analysis on UP trial.
Anticipate ovarian 2A trial (mechanism of action) will start later this quarter or early 2017.
1st half 2017: Prurisol interim analysis, OM interim analysis, complete Phase 2 of UP. Then Phase 2 of psoriasis and K proof of concept, and the OM trial
ABSSSI study: timetable depends on FDA agreement.
(3)
(0)
